- Investing.com
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Market Leader's Edge | Zoetis dominates animal health with robust organic growth and innovative products, showcasing resilience amid economic challenges |
Product Powerhouses | Explore Zoetis's key franchises like Librela and Apoquel, driving impressive growth despite market hurdles and competitive pressures |
Strategic Expansion | Delve into Zoetis's untapped market potential in Allergy Dermatitis and Pain management, bolstered by a diverse pipeline of next-gen treatments |
Financial Forecast | Analysts project steady earnings growth with EPS estimates ranging from $5.79 to $6.48 over two years, and an average price target of $230 |
Metrics to compare | ZTS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZTSPeersSector | |
---|---|---|---|---|
P/E Ratio | 35.2x | −3.1x | −0.6x | |
PEG Ratio | 4.74 | 0.08 | 0.00 | |
Price/Book | 16.6x | 1.4x | 2.6x | |
Price / LTM Sales | 9.2x | 2.2x | 3.2x | |
Upside (Analyst Target) | 17.6% | 63.5% | 48.6% | |
Fair Value Upside | Unlock | 12.8% | 7.0% | Unlock |